it has been used in trials studying the treatment of HIV-1. it is a next-generation, pyrazole non-nucleoside reverse transcriptase inhibitor. it retains activity against HIV viruses with mutations at position Y181, which confers resistance to efavirenz, etravirine, and nevirapine. 
